E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060862 |
E.1.2 | Term | Prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective
We propose a study to test whether it is possible to improve the outcome of prostate radiotherapy using simple, cost-effective measures. Carbogen gas (98% oxygen and 2% carbon dioxide) and nicotinamide (vitamin B3) will be given in conjunction with standard prostate radiotherapy. Disease control, survival and toxicity will be measured. The study aims to determine the efficacy of carbogen gas breathing and nicotinamide tablets, given during a course of intensity-modulated radiotherapy to the prostate gland in previously untreated patients with prostate cancer.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives
To describe the toxic effects of the combination of prostate radiotherapy with carbogen and nicotinamide.
To describe the time to progression, the proportion achieving PSA control following radiotherapy, the local control rate and overall survival.
Imaging research will explore: (1) Whether hypoxia modification benefits tumours previously treated with hormones to an even greater extent that hormone-naive cancers. (2) The way radiotherapy alters the extent and distribution of oxygen within prostate tumours, which will be important for the development of biologically-targeted radiotherapy. (3) Whether imaging studies can predict which patients may benefit most from hypoxic modification.
Laboratory research will attempt to determine whether markers of tumour oxygen levels derived from special stains of prostate tissue can be used to determine prognosis following radiotherapy for prostate cancer and which patients may benefit from hypoxia modification. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Histological diagnosis of prostate adenocarcinoma of Gleason grade 3+3 or higher •Radical radiotherapy is considered to be appropriate treatment •Any of: PSA > 20ng/ml, Gleason grade > 8, T3 disease on MRI •Patients must have radiographically documented measurable disease on pelvic MRI scan within 3 months of trial entry •Age over 18 with no upper age limit •Before patient registration, written informed consent must be given according to GCP and local regulations.
|
|
E.4 | Principal exclusion criteria |
•Metastatic disease (including pelvic lymph node metastases) on conventional imaging including pelvic MRI scan and isotope bone scan within 3 months of trial entry •PSA>50 •T4 disease on pelvic MRI scan within 3 months of trial entry •Prior treatment for prostate cancer, either local or systemic (other than neo-adjuvant androgen deprivation for a period of less than 3 months) •Current active malignancy other than prostate cancer or non-melanomatous skin cancer •Previous radiotherapy to the pelvis •Co-morbid conditions such that the technique of external beam radiotherapy is inappropriate •Contraindication to MRI (only applicable to patients that are being considered for entry into the imaging component of the study) •Current treatment with an ACE inhibitor •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is biochemical relapse
Biochemical relapse will be defined according to the RTOG-ASTRO ‘Phoenix’ definition of relapse and is defined as PSA nadir +2ng/ml, with time to relapse being defined as the time from the first day of treatment to the date of the PSA blood sample that exceeds the nadir +2ng/ml threshold.
The primary endpoint is biochemical relapse-free survival
Biochemical relapse-free survival will be defined as:
• The time from the 1st day of treatment to biochemical relapse or • The time from the 1st day of treatment to censorship
Patients will be censored at the time they are withdrawn from the trial for any reason or in the case of them being lost to follow-up, at the time of their last assessment.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patients will be assessed for biochemical relapse at 2, 4, 12 and 26 weeks after treatment by using a serum PSA blood test. Thereafter they will be assessed at six monthly intervals for a total of five years. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints are:
Overall relapse-free survival Overall survival Safety profile (as measured by CTCAEv4.0) Quality of life (as measured by IPSS, FACT-P, IIEF-5 and drug use) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patients will be assessed for these end points at 2, 4, 12 and 26 weeks after treatment. Thereafter they will be assessed at six monthly intervals for a total of five years. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit of the last subject undergoing the trial. This will be the 5 year follow-up appointment of the last participant |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 30 |